MX2022009931A - Ligandos de proteina de activacion de fibroblastos para aplicaciones de administracion dirigida. - Google Patents

Ligandos de proteina de activacion de fibroblastos para aplicaciones de administracion dirigida.

Info

Publication number
MX2022009931A
MX2022009931A MX2022009931A MX2022009931A MX2022009931A MX 2022009931 A MX2022009931 A MX 2022009931A MX 2022009931 A MX2022009931 A MX 2022009931A MX 2022009931 A MX2022009931 A MX 2022009931A MX 2022009931 A MX2022009931 A MX 2022009931A
Authority
MX
Mexico
Prior art keywords
activation protein
fibroblast activation
targeted delivery
fap
delivery applications
Prior art date
Application number
MX2022009931A
Other languages
English (en)
Inventor
Ilaria Biancofiore
Samuele Cazzamalli
Plaza Sheila Dakhel
Etienne J Donckele
Jacopo Millul
Florent Samain
Eleonore Schmidt
Original Assignee
Philochem Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Philochem Ag filed Critical Philochem Ag
Priority claimed from PCT/EP2021/053494 external-priority patent/WO2021160825A1/en
Publication of MX2022009931A publication Critical patent/MX2022009931A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Optics & Photonics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La presente invención se refiere a ligandos de proteína de activación de fibroblastos (FAP, por sus siglas en inglés) para el suministro activo de varias cargas útiles (por ejemplo, fármacos citotóxicos, radionúclidos, fluoróforos, proteínas e inmunomoduladores) en el sitio de enfermedad. En particular, la presente invención se relaciona con el desarrollo de ligandos de FAP para aplicaciones de direccionamiento, en particular métodos de diagnóstico y/o métodos para terapia o cirugía en relación con una enfermedad o trastorno, tal como cáncer, inflamación u otra enfermedad caracterizada por sobreexpresión de FAP.
MX2022009931A 2020-02-12 2021-02-12 Ligandos de proteina de activacion de fibroblastos para aplicaciones de administracion dirigida. MX2022009931A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP20157036 2020-02-12
EP20172953 2020-05-05
EP20202856 2020-10-20
PCT/EP2021/053494 WO2021160825A1 (en) 2020-02-12 2021-02-12 Fibroblast activation protein ligands for targeted delivery applications

Publications (1)

Publication Number Publication Date
MX2022009931A true MX2022009931A (es) 2022-09-12

Family

ID=83225945

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022009931A MX2022009931A (es) 2020-02-12 2021-02-12 Ligandos de proteina de activacion de fibroblastos para aplicaciones de administracion dirigida.

Country Status (8)

Country Link
JP (1) JP2023514275A (es)
KR (1) KR20220154111A (es)
CN (2) CN115335370B (es)
AU (1) AU2021220663A1 (es)
BR (1) BR112022016049A2 (es)
CA (1) CA3171025A1 (es)
IL (1) IL295571A (es)
MX (1) MX2022009931A (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024198836A1 (zh) * 2023-03-27 2024-10-03 晶核生物医药科技(南京)有限公司 环状多肽类化合物及其应用
CN116925041A (zh) * 2023-06-12 2023-10-24 上海交通大学医学院附属仁济医院 靶向成纤维细胞激活蛋白的氟标记放射性药物前体、放射性标记化合物及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112105354A (zh) * 2017-12-15 2020-12-18 普拉西斯生物技术有限责任公司 成纤维细胞激活蛋白抑制剂
SG11202007180QA (en) * 2018-02-06 2020-08-28 Univ Heidelberg Fap inhibitor

Also Published As

Publication number Publication date
CN118812631A (zh) 2024-10-22
CN115335370A (zh) 2022-11-11
IL295571A (en) 2022-10-01
BR112022016049A2 (pt) 2022-11-16
AU2021220663A1 (en) 2022-10-06
KR20220154111A (ko) 2022-11-21
CN115335370B (zh) 2024-08-23
JP2023514275A (ja) 2023-04-05
CA3171025A1 (en) 2021-08-19

Similar Documents

Publication Publication Date Title
MX2023009486A (es) Ligandos bivalentes de la proteína de activación de fibroblastos para aplicaciones de entrega dirigida.
MX2007009960A (es) Combinaciones y metodos de administracion de agentes terapeuticos y terapia de combinacion.
PH12019502545A1 (en) Anti-cdh6 antibody and anti-cdh6 antibody-drug conjugate
MX2022009931A (es) Ligandos de proteina de activacion de fibroblastos para aplicaciones de administracion dirigida.
MX2009004803A (es) Nanoparticulas de paclitaxel y albumina en combinacion con bevacizumab contra el cancer.
MX2022002592A (es) Conjugado de anticuerpo-farmaco que comprende un anticuerpo contra el gen del receptor huerfano 1 similar a tirosina cinasa receptora (ror1) humano y uso para el mismo.
BR112015030377A2 (pt) preparação compreendendo pelo menos um quimioterápico ou substância citotóxica para uso no tratamento de uma doença de um paciente mamífero, preparação e método para tratamento de câncer em um paciente mamífero através de terapia de radiação
EA201390681A1 (ru) Производные полипептиды il-2 с агонистической активностью для лечения рака и хронических инфекций
MX2018004177A (es) Terapia de combinacion para el tratamiento de cancer.
MX2021009199A (es) Conjugado de farmaco de dos ligandos y uso del mismo.
IN2015KN00350A (es)
EA200802350A3 (ru) Система доставки лекарств
ZA202302155B (en) Interferon-based cancer treatment method and pharmaceutical composition
WO2017062615A3 (en) Combination therapy for the treatment of cancer
MX2024004077A (es) Ligandos de proteina de activacion de fibroblastos radioetiquetados.
Singh et al. A grafted peptidomimetic for EGFR heterodimerization inhibition: Implications in NSCLC models
WO2011050178A3 (en) Targeted prdm gene or protein modulation therapeutic agents
PH12020551715A1 (en) Methods of treating cancer
WO2019028281A3 (en) OPTIMIZED PEPTIDES FOR TARGETING HUMAN NERFS AND THEIR USE IN GUIDED SURGERY THROUGH THE IMAGING, DIAGNOSTICS AND ADMINISTRATION OF THERAPEUTIC AGENTS
ES2874668T3 (es) Conjugados anticuerpo-fármaco dirigidos a uPARAP
EA202092369A1 (ru) Конъюгаты фосфолипид-флаваглин и способы их применения для целенаправленной терапии рака
WO2022174064A3 (en) Therapeutic composition and method combining multiplex immunotherapy with cancer vaccine for the treatment of cancer
WO2019055776A3 (en) Compositions and methods for treatment of diseases involving cxcl1 function
Li et al. Calcium Carbonate/Polydopamine Composite Nanoplatform Based on TGF-β Blockade for Comfortable Cancer Immunotherapy
NZ708860A (en) Use of antisecretory factor (af) in glioblastoma treatment